The Claim
In patients with acute coronary syndrome after percutaneous coronary intervention, a PDCA cycle-based lipid-lowering strategy results in a 38.9% rate of achieving an intensive LDL-C target of <1.4 mmol/L at 12 weeks, compared to a 15.2% rate with standard care.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Among patients recovering from a heart procedure, using a structured management approach called a PDCA cycle to lower cholesterol leads to nearly 39% reaching a very low LDL target at 12 weeks, while standard care achieves this in only 15% of cases.
See the scientific wording
In patients with acute coronary syndrome after percutaneous coronary intervention, a PDCA cycle-based lipid-lowering strategy is associated with a 38.9% rate of achieving an intensive LDL-C target of <1.4 mmol/L at 12 weeks, compared to 15.2% with standard care, indicating a substantial improvement in reaching guideline-recommended levels for very-high-risk patients.
When patients take their cholesterol-lowering medicines exactly as planned, the liver removes more bad cholesterol from the blood by making more receptors that grab it and pull it out.
What the research says
1 studyAfter a heart attack and stent, patients who followed a structured, step-by-step plan to manage their cholesterol were much more likely to reach their low cholesterol goals than those who got regular care. This plan helped them take their meds better and live healthier, leading to much better results.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.